TLR9 and metabolic dysfunction-associated steatohepatitis: Previous research has shown that TLR9 signaling promotes KC production of interleukin-1β (IL-1β) in a mouse model of NASH, contributing to steatosis, inflammation, and fibrosis (Shepard, 2020).